LT
Therapeutic Areas
Dialectic Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DT2216 | Fibrolamellar Carcinoma | Phase 1/2 |
Leadership Team at Dialectic Therapeutics
JD
John D. Harkey Jr., JD, MBA
Executive Chairman & Co-founder
JS
Joshua Sills
Chief Operating Officer
SF
Stephen Friedberg
Chief Financial Officer
JS
James Strauss, MD
Chief Medical Officer
GZ
Guangrong Zheng, PhD
Director of Medicinal Chemistry & Scientific Co-founder